background studied maximum tolerated dose mtd efficacy oxaliplatin added capecitabine radiotherapy neoadjuvant therapy rectal cancer methods rectal cancer patients received escalating doses oxaliplatin day NUMBER NUMBER fixed dose capecitabine NUMBER twice daily days NUMBER added rt NUMBER gy surgery weeks mtd determined phase used subsequent phase ii r0 resection rate negative circumferential resection margin primary end point results patients evaluable phase oxaliplatin NUMBER established mtd phase ii main toxicity grade iii diarrhea NUMBER patients underwent surgery NUMBER patients resectable tumor r0 achieved patients downstaging pcr conclusion combination acceptable acute toxicity profile high r0 resection rate NUMBER locally advanced rectal cancer pcr rate low capox rt t3 NUMBER NUMBER NUMBER NUMBER NUMBER t0 NUMBER capox rt mg m2 mg m2 NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER